聚甘油-3油酸酯 | 33940-98-6

• 物质功能分类: 催化剂及助剂 - 聚合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 聚甘油-3油酸酯
• 中文别名: 三聚甘油单油酸酯
• 英文名称: Tetraglyceryl monooleate
• 英文别名: [3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl] (Z)-octadec-9-enoate
• CAS: 33940-98-6
• 化学式: C₂₇H₅₂O₈
• 分子量: 504.7
• InChiKey: SJLAFUFWXUJDDR-KTKRTIGZSA-N

物化性质

• 闪点：
  95℃

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  35
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US10231985B2

  公开（公告）日：2019-03-19

  The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.

  本发明涉及医学领域。所述血脂异常通常与生物膜（包括非脂肪细胞的生物膜）中脂肪酸（尤其是饱和长链脂肪酸）和/或甾醇的过量存在有关。本发明还涉及包含此类化合物的组合物，特别是药物组合物和食品补充剂或补品，以及其在预防和/或治疗血脂异常方面的用途。根据本发明的化合物和组合物尤其可有利地用于预防和/或治疗选自代谢综合征和/或代谢综合征特征性症状或异常的病理状况，最好用于预防或治疗 2 型糖尿病或肝脂肪变性。
• COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20160256429A1

  公开（公告）日：2016-09-08

  The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.
• COMPOUNDS, COMPOSITIONS AND CORRESPONDING USES FOR PREVENTING AND/OR TREATING OF DYSLIPIDEMIA
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：US20160287542A1

  公开（公告）日：2016-10-06

  The present invention relates to the field of medicine. It relates more particularly to the use of compounds to prevent and/or treat lipotoxicity in a subject, especially lipotoxicity by hypoxia. The invention relates more particularly to compositions, especially pharmaceuticals compositions and nutritional supplements or complements comprising such compounds as well as their use to prevent and/or treat lipotoxicity, especially lipotoxicity by hypoxia. The compounds and compositions of the invention can especially be advantageously used to prevent and/or treat a pathology from among pulmonary pathologies, especially cystic fibrosis or a chronic obstructive pulmonary disease.
• US9821000B2
  申请人：——

  公开号：US9821000B2

  公开（公告）日：2017-11-21